299
Views
16
CrossRef citations to date
0
Altmetric
Urology

Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer

, , &
Pages 113-121 | Received 28 Nov 2009, Accepted 15 Oct 2010, Published online: 22 Nov 2010

References

  • Murphy W. Current status of urinary cytology in evaluation of bladder neoplasms. Hum Pathol 1990;21:886–96.
  • Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, FinnBladder Group. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284–9.
  • Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with haematuria. J Urol 2006;176:44–7.
  • Schmitz-Drager BJ, Beiche B, Tirsar LA, Schmitz-Drager C, Bismarck E, Ebert T. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 2007;51:1582–8.
  • Bott S, Chanawani M, Mostafid H. The use of the NMP22 bladdercheck test for bladder cancer to optimize investigations in a one-stop haematuria clinic. Br J Med Sci Surg Urol 2008;1:126–30.
  • McNeil BK, Getzenberg RH. Urine-based markers in bladder cancer: future prospects BJU Int 2008;101:668–9.
  • Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 2008;26:39–44.
  • Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology 2005;66:35–63.
  • Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science 1945;101:519–20.
  • van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systemic review. Eur Urol 2005;47:736–48.
  • Miyanaga N, Akaza H, Tsukamoto S, Shimazui T, Ohtani M, Ishikawa S, Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 2003;8:369–73.
  • Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002;167:80–3.
  • Nielsen ME, Schaffer EM, Veltri RW, Schoenberg MP, Getzenberg RH. Urinary markers in the detection of bladder cancer: what's new? Curr Opin Urol 2006;16:350–5.
  • Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol 2006;24:326–37.
  • Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53–7e.
  • Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295:299–305.
  • Witjes JA, van der Poel HG, van Balken MR, Debruyne FMJ, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998;33:387–91.
  • Lokeshwar VB, Selzer MG. Urinary bladder tumor markers. Urol Oncol 2006;24:528–37.
  • Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 2009;43:461–6.
  • Villicana P, Whiting B, Goodison S, Rosser CJ. Urine based assays for the detection of bladder cancer. Biomark Med 2009;3:265–70.
  • Herr HW, Donat SM. A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences. BJU Int 2008;102:1111–14.
  • Lotan Y, Shariat SF, NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008;101:1362–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.